Why the study?
Major clinical consequences of atherosclerosis stem from thrombotic events linked to unstable plaque rupture or erosion, prompting investigation into molecular regulators of plaque stability.
Does Nron knockdown improve atherosclerotic plaque stability in preclinical models?
Does Nron knockdown improve atherosclerotic plaque stability in preclinical models?
Nron is a critical regulator of atherosclerotic plaque stability, suggesting its genetic or pharmacological inhibition could be a potential therapeutic target for atherosclerosis.
Answers are grounded in this paper and cite their sources.
Nron modulation may influence experimental plaque stability; leaves open whether this lncRNA is a viable therapeutic target in human atherosclerosis.
The major clinical consequences of atherosclerosis such as myocardial infarction or stroke are because of thrombotic events associated with acute rupture or erosion of an unstable plaque. Here, we identify an lncRNA Noncoding Repressor of NFAT (Nron) as a critical regulator of atherosclerotic plaque stability. Nron overexpression (OE) in vascular smooth muscle cells (VSMC) induces a highly characteristic architecture of more-vulnerable plaques, while Nron knockdown (KD) suppresses the development of atherosclerosis and favors plaque stability. Mechanistically, Nron specifically binds to and negatively regulates NFATc3, thus inhibiting the proliferation and promoting the apoptosis of VSMCs. Moreover, we also provide evidence that Nron increases the production and secretion of VEGFA from VSMCs, which functions as a paracrine factor to enhance intra-plaque angiogenesis. All of these effects contribute to plaque instability. Genetic or pharmacological inhibition of Nron may have potential for future therapy of atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Du et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: